Healthcare: 2 Hot Biotech Stocks On Our Radar

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 26 September 2018

⏱️ 35 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

How Regenxbio is capitalizing on the emerging gene therapy trend and why Neurocrine Biosciences is on the cusp of making the jump to profitability. Also, how Amarin may revolutionize how doctors treat heart disease. Stocks: RGNX, NVS, NBIX, ABBV, AMRN.

Transcript

Click on a timestamp to play from that location

0:00.0	This episode of Industry Focus is brought to you by Sinios Health, a new fully integrated
0:05.2	bio-pharmaceutical Solutions Organization that's the result of a merger between INC research
0:11.0	and inventive health. Sinios Health is focused on a simple and Inc.
0:13.0	Cineos Health is focused on a simple end goal.
0:16.0	Shortening the distance from lab to life.
0:19.0	To learn more, visit Cineos Health.
0:21.0	dot com slash podcast. Cineos Health.com. Paudcast.
0:24.0	Welcome to Industry Focus, the show that dives into a different sector of the stock market every day.
0:31.0	Today is Wednesday, September 26, and we're talking health care.
0:35.6	I'm your host Shannon Jones.
0:37.0	I'm joined in the studio with Motley Fool contributor Todd Campbell via Skype. On today's show we're diving
0:44.9	into one of the most widely anticipated trial readouts for Amarin and their
0:49.8	fish oil pill believe it or not and we'll also be revealing our favorite biotech
0:54.6	picks. That's all in this week's episode of industry-focused health care but
1:00.3	Todd I don't know about you but but for me, September has been a wild and very interesting month for the bio-farma world.
1:08.0	Oh, absolutely, and it got to
1:14.1	you know rank in the top five at least of of
1:18.0	of crazy things that we've seen in Bio Pharma this month maybe if not higher
1:22.3	Yeah, I definitely would say it's got to be with in Bio- Pharma this month, maybe if not higher.
1:23.0	Yeah, I definitely would say it's got to be within the top five.
1:25.9	I would dare say it's probably, maybe number two or three even, just given the anticipation
1:31.8	leading up to the trial,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.